We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
An IT recruitment and training site launched to meet the demands of enterprises that require highly skilled tech professionals. 365 Talent Portal offers companies to hire IT consultants at a lower price compared to traditional recruitment hubs. The company also allows IT professionals registered on the site to access training and certification programmes that will expand their current skillset and become more marketable to potential employers. 365 Talent Portal is raising funds to produce more prominent marketing campaigns and establish their brand in major markets such as the USA. In addition to this, the company will be using AI more heavily and develop a more automated approach on their platform for their customers.
days to go: Expired investment: £156,000
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Billon have created a technology that enables zero cost global payments by the use of a simple mobile app. Billon's mobile app allows you to instantly pay for the rest of an article from the Guardian or even donate to your favourite Youtubers with a few clicks of a button. 
days to go: Expired investment: £1,406,667
Cyance is an award-winning marketing technology pioneer. Nexus is a software platform designed by the company to track the buying behaviour through billions of computers belonging to millions of businesses across the globe. This platform can track the consumed content and identifies customer interests and needs. The company's customers typically generate x3 more leads and x4 more sales. With the proceeds, Cyance will increase its marketing sales and improve product development to fund the general working capital.
days to go: Expired investment: Withheld
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go: Expired investment: £1,149,999
ITIG have developed software to aid in understanding the investment process, as well as reducing the associated costs of investing. Using their licensed methodologies, retail and institutional investors will see return funds which are more predictable when investing in Exchange Traded Funds (ETFs), resulting in highly diverse and low-cost investment portfolio.
days to go: Expired investment: £67,000
Jobhawk is the UK’s first digital marketplace for construction labour. They aim to make it possible for sub-contractors to get self-employed labour instantly for their projects. They have developed an app that matches the UK's leading subcontractors with bricklayers, carpenters and other tradesmen, with less effort for everyone involved.
days to go: Expired investment: £728,573
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
Orthogem is a UK based manufacturer of synthetic bone grafts. Synthetic bone grafts are substitutes for human bone grafts and are designed to replace bone that has been lost. Orthogem have recently started to produce their product in a putty form in order to keep up with the changes in the market. 
days to go: Expired investment: £722,784
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph